Zanubrutinib for older patients with untreated CLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a targeted therapy called zanubrutinib for people aged 80 and older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It may help control the disease with fewer side effects than standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 80 years old or older.
- You must have CLL or SLL that has not been treated before and now needs therapy.
- You must have a good performance status (able to do daily activities with some help).
- You need adequate blood counts, kidney and liver function.
- You cannot have had prior CLL treatment or certain heart conditions or recent bleeding issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It aims to see if using these drugs early can help achieve better deep responses.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a combination of three drugs (zanubrutinib, sonrotoclax, and obinutuzumab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment before. The goal is to see if this combination works well and is safe.
This trial tests a new drug, pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) who have already been treated with zanubrutinib (a similar BTK inhibitor). The goal is to see if switching to pirtobrutinib can help control the disease.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.